Clinical Trial Update: Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE [Phase 4]

View source ↗

Summary

Phase 4 trial update on antibody persistence to REVAXIS or DT polio and immune response to TETRAVAC-ACELLULAIRE completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Poliomyelitis
• Tetanus

Drugs mentioned

• DT polio vaccine (diphtheria-tetanus-pertussis/polio vaccine)
• Revaxis (Diphtheria-Tetanus-Acellular Pertussis and Inactivated Poliovirus Vaccine)
• TETRAVAC-ACELLULAIRE

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Diphtheria, Tetanus | Phase 4 | Status: COMPLETED